Stellabody® technology in cancer therapy

Our aim is to apply Stellabody® technology to a broad range of antibodies and bring these to clinical trials for cancer treatment.

Using Stellabody® technology we can transform the actions of antibodies into potent killers of cancer, potentiating them to be as much as 100 times more effective at killing. We can modify existing antibody medicines to make them kill more cancers or take antibodies that cannot kill and transform them into potent killers of cancer cells. We are applying our multifaceted Stellabody® hexamer technology to direct the human immune system to destroy cancer cells either by activation of the complement system and Fc receptors on inflammatory cells, or by apoptosis through the activation of death receptors.

In blood cancers we are evaluating the Stellabody® hexamer technology in existing antibody medicines that bind to known targets in lymphoma, leukaemia and multiple myeloma. We have shown the Stellabody™ modification of anti-cancer monoclonal antibodies (mAbs) – such as isatuximab and daratumumab (CD38 mAbs) in multiple myeloma and CD20 mAbs in lymphoma makes them potent killers of cancer cells. We are also evaluating Stellabody® antibodies to new targets for treatment. 
 
In solid tumours such as colon, ovarian and breast cancers we apply our Stellabody® hexamer technology to induce the death of cancer cells by a process called apoptosis or programmed cell death. Applying the Stellabody® technology to mAbs that target ‘death receptors’ on cancer cells induces extremely potent death signals that kill only the target cells. The on-target hexamerisation by Stellabody® death receptor-specific mAbs increases death receptor clustering on the cell. This clustering amplifies the death receptor signals leading to apoptosis-induced cell death and the elimination of the cancer cells.